Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

Next Previous
X
Search
Trial Profile

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 0804 (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms LIMBER; LIMBER-TREG108; TREG108
  • Sponsors Cellenkos

    • Most Recent Events

    • 04 Jun 2024 Preliminary results from this trial presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 15 Dec 2023 Planned primary completion date changed from 30 Oct 2023 to 30 Apr 2024.
    • 12 Dec 2023 Results (As of 1st of July 2023, n=5) assessing safety and clinical activity of CK0804 in Participants with Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top